We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly (LLY) Phase III Eczema Study on Lebrikizumab Meets Goal
Read MoreHide Full Article
Eli Lilly & Company (LLY - Free Report) announced data from two pivotal phase III studies, which showed that its investigational IL-13 inhibitor, lebrikizumab significantly improved skin clearance and itch in patients with moderate-to-severe atopic dermatitis (“AD”), also called eczema.
The phase III ADvocate 1 and ADvocate 2 studies met the primary and all key secondary endpoints, including skin clearance and itch improvement, at Week 16.
The top-line data from the two studies showed that more than half the patients treated with lebrikizumab, as a monotherapy, experienced at least 75% skin clearance as measured by Eczema Area and Severity Index (EASI) score. Full data from the two studies will be presented at a future medical meeting.
Lebrikizumab was added to Lilly’s portfolio with the acquisition of Dermira in February 2020.The FDA had earlier granted Fast Track designation to lebrikizumab for moderate-to- severe AD in adult and adolescent patients. The candidate is also being evaluated in a phase III combination study (ADhere) with topical corticosteroids in AD, data from which is expected to be available later this year.
Lilly’s stock has risen 59.8% this year so far compared with an increase of 17.2% for the industry.
Image Source: Zacks Investment Research
Lebrikizumab is part of Lilly’s immunology pipeline, which also includes candidates like mirikizumab, being studied in late-stage studies for ulcerative colitis and Crohn's disease. Key marketed drugs in Lilly’s immunology portfolio include, Taltz and Olumiant.
In a separate press release, Lilly announced that the FDA has approved a new delivery option for Lyumjev, its new rapid-acting insulin. Lyumjev 100 units/mL has been approved for use in an insulin pump to improve glycemic control in adults with type I and II diabetes. Lyumjev, a new fast-acting formulation of Lilly’s insulin lispro (Humalog), was approved by the FDA in June last year.
Some better-ranked stocks from the biotech sector include Horizon Therapeutics , Regeneron (REGN - Free Report) and Repligen Corporation (RGEN - Free Report) , all with a Zacks Rank #1.
Horizon Therapeutics’ earnings estimates have increased from $3.62 to $4.46 per share for 2021 and from $5.34 to $5.84 per share for 2022 in the past 30 days. The stock has risen 45.3% so far this year.
Regeneron’s earnings per share estimates have moved north from $49.53 to $54.15 for 2021 and from $41.35 to $44.11 for 2022 in the past 30 days. The stock has risen 30.2% so far this year.
Repligen’s earnings per share estimates have risen from $2.26 to $2.76 for 2021 and from $2.56 to $3.02 for 2022 in the past 30 days. The stock has risen 33.6% so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
Lilly (LLY) Phase III Eczema Study on Lebrikizumab Meets Goal
Eli Lilly & Company (LLY - Free Report) announced data from two pivotal phase III studies, which showed that its investigational IL-13 inhibitor, lebrikizumab significantly improved skin clearance and itch in patients with moderate-to-severe atopic dermatitis (“AD”), also called eczema.
The phase III ADvocate 1 and ADvocate 2 studies met the primary and all key secondary endpoints, including skin clearance and itch improvement, at Week 16.
The top-line data from the two studies showed that more than half the patients treated with lebrikizumab, as a monotherapy, experienced at least 75% skin clearance as measured by Eczema Area and Severity Index (EASI) score. Full data from the two studies will be presented at a future medical meeting.
Lebrikizumab was added to Lilly’s portfolio with the acquisition of Dermira in February 2020.The FDA had earlier granted Fast Track designation to lebrikizumab for moderate-to- severe AD in adult and adolescent patients. The candidate is also being evaluated in a phase III combination study (ADhere) with topical corticosteroids in AD, data from which is expected to be available later this year.
Lilly’s stock has risen 59.8% this year so far compared with an increase of 17.2% for the industry.
Image Source: Zacks Investment Research
Lebrikizumab is part of Lilly’s immunology pipeline, which also includes candidates like mirikizumab, being studied in late-stage studies for ulcerative colitis and Crohn's disease. Key marketed drugs in Lilly’s immunology portfolio include, Taltz and Olumiant.
In a separate press release, Lilly announced that the FDA has approved a new delivery option for Lyumjev, its new rapid-acting insulin. Lyumjev 100 units/mL has been approved for use in an insulin pump to improve glycemic control in adults with type I and II diabetes. Lyumjev, a new fast-acting formulation of Lilly’s insulin lispro (Humalog), was approved by the FDA in June last year.
Zacks Rank and Stocks to Consider
Lilly currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Some better-ranked stocks from the biotech sector include Horizon Therapeutics , Regeneron (REGN - Free Report) and Repligen Corporation (RGEN - Free Report) , all with a Zacks Rank #1.
Horizon Therapeutics’ earnings estimates have increased from $3.62 to $4.46 per share for 2021 and from $5.34 to $5.84 per share for 2022 in the past 30 days. The stock has risen 45.3% so far this year.
Regeneron’s earnings per share estimates have moved north from $49.53 to $54.15 for 2021 and from $41.35 to $44.11 for 2022 in the past 30 days. The stock has risen 30.2% so far this year.
Repligen’s earnings per share estimates have risen from $2.26 to $2.76 for 2021 and from $2.56 to $3.02 for 2022 in the past 30 days. The stock has risen 33.6% so far this year.